Cited in:


This article has been cited by:

  1. 1
    Laurent L. Reber, Nelly Frossard, Targeting mast cells in inflammatory diseases, Pharmacology & Therapeutics, 2014, 142, 3, 416


  2. 2
    Thierry Olivry, Petra Bizikova, A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008–2011 update, Veterinary Dermatology, 2013, 24, 1
  3. 3
    M.R. Brown, R.E. Cianciolo, M.B. Nabity, C.A. Brown, F.J. Clubb, G.E. Lees, Masitinib-Associated Minimal Change Disease with Acute Tubular Necrosis Resulting in Acute Kidney Injury in a Dog, Journal of Veterinary Internal Medicine, 2013, 27, 6
  4. 4
    Jon D. Plant, Kinga Gortel, Marcel Kovalik, Nayak L. Polissar, Moni B. Neradilek, Development and validation of the Canine Atopic Dermatitis Lesion Index, a scale for the rapid scoring of lesion severity in canine atopic dermatitis, Veterinary Dermatology, 2012, 23, 6
  5. You have free access to this content5
    S. E. Lyles, R. J. Milner, K. Kow, M. E. Salute, In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines, Veterinary and Comparative Oncology, 2012, 10, 3
  6. 6
    J. Lawrence, C. Saba, R. Gogal, O. Lamberth, M. L. Vandenplas, D. J. Hurley, P. Dubreuil, O. Hermine, K. Dobbin, M. Turek, Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells, Veterinary and Comparative Oncology, 2012, 10, 2
  7. 7
    Thierry Olivry, Petra Bizikova, A Systematic Review of Randomized Controlled Trials for Prevention or Treatment of Atopic Dermatitis in Dogs: 2008–2011 Update,
  8. 8